PATHOQUEST
24.11.2021 13:02:07 CET | Business Wire | Press release
PathoQuest, a leading contract research organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies, today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124005881/en/
This GMP certification acknowledges PathoQuest's testing activities meet the established high-quality control standards required by the biopharmaceutical industry. Biotech and biopharma companies may now transition from early-stage projects to more advanced clinical phases and commercial batch release using the power and precision of the NGS technology. PathoQuest today offers viral safety testing services and genetic characterization of biologics.
"Obtaining the GMP certification confirms that our quality management system meets the requirements and is at the expected level by the health authorities,” stated Violaine Mélen, PharmD, PathoQuest’s Chief Quality Assurance & Regulatory Affairs Officer and Qualified Person. The GMP certification for our biosafety testing services completes our GLP certificate obtained in January 2020 and the Pharmaceutical Establishment status achieved in September 2020. Offering GMP-grade genomic testing services is our pledge of quality to the biopharmaceutical industry, the health authorities and for the safety of the patient.
“Gaining this GMP certification is a major milestone in the implementation of PathoQuest’s growth strategy and strengthens our leadership in the quality control testing of biologics,” commented Jean-Francois Brepson, PathoQuest’s CEO . "By offering these testing services we will enable our clients to entrust their vaccine, cell and gene therapy, and other innovative therapies projects to PathoQuest, from early preclinical phases to commercial supply. We believe this represents a tremendous advantage for biopharmaceutical companies when they evaluate contract manufacturing alternatives that are faster, safer and 3R-compliant at a Good Manufacturing Practice grade. Those assets make PathoQuest the ideal partner.”
PathoQuest’s GMP certificate is available for our clients to download from our website along with the company’s current GLP certificate and the notice of achieving Pharmaceutical Establishment status.
About PathoQuest
PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, GLP and GMP grades to ensuring the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.
For more information, visit www.pathoquest.com or contact us at welcome@pathoquest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 09:00:00 CEST | Press release
IIOR Shows Record Outsourced Insurance AUM, Private Assets Near $1 Trillion, and Europe Emerging as a Global Growth Engine Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 08:00:00 CEST | Press release
Two new capabilities give multi-site manufacturers standardized workflows, traceable records, and automated reporting across every plant. Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Qu
The LYCRA Company to Successfully Complete Comprehensive Financial Restructuring20.5.2026 04:23:00 CEST | Press release
Company positioned for long-term growth, operational excellence, and continued customer-focused innovationWill emerge from financial restructuring with enhanced financial flexibility and significantly less debtNew ownership and Board of Directors committed to executing on vision to take the business to the next levelBruce Rubin appointed Executive Chairman and Dean Williams appointed Interim Chief Executive Officer The LYCRA Company, LLC (“the Company”), a global leader in developing fiber and technology solutions for the apparel and personal care industries, will successfully complete its comprehensive financial restructuring process and emerge from Chapter 11 protection on May 20, 2026. The LYCRA Company has established a durable capital structure that will enable the Company’s pursuit of its growth strategy through investment in innovation, customer partnerships, and global operations. The Company will emerge from its comprehensive restructuring process with significantly enhanced f
Johns Manville Announces John Vasuta as New CEO19.5.2026 22:30:00 CEST | Press release
Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will retire and John Vasuta will assume the role of President and Chief Executive Officer, effective August 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519630814/en/ John Vasuta will become JM's CEO and President on August 1, 2026. Vasuta joined Johns Manville in 2019 as President of the company’s Engineered Products business. He also serves on the Board of Directors for EJ, a global leader and private manufacturer of infrastructure access products for water, sewer, utilities, drainage and telecommunications. “It’s an extraordinary privilege to step into the role of CEO,” Vasuta said. “I’m deeply honored to continue serving our customers and supporting the employees whose dedication makes our success possible.” Before joining JM, John held leadership roles at Bridgeston
Mereo Insurance Announces Move into Excess Casualty Insurance19.5.2026 22:12:00 CEST | Press release
Mereo expands into Excess Casualty Insurance by acquiring renewal rights to Everen Specialty Ltd.’s Excess Casualty Energy portfolio. Mereo Insurance Limited (“Mereo”) today announced a renewal rights transaction with Everen Specialty Ltd. (“ESL”), a member of the Everen Group, for ESL’s Excess Casualty Energy portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519154915/en/ David Croom-Johnson, President & Chief Executive Officer of Mereo Insurance Limited Under the transaction, Mereo will become the insurance carrier on a go-forward basis for both new and renewed business effective June 1, 2026. ESL’s underwriting team and underwriting systems supporting the Excess Casualty Energy portfolio will also transition to Mereo, led by former ESL Chief Underwriting Officer, Carla Greaves. Under the terms of the agreement, Mereo will provide ESL insureds with continuity of coverage, access to AM Best “A- rated” paper, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom